

SEMA5A in Parkinson's disease

Dear Editor,

I have read with interest the recent paper by Yu and coworkers¹ on the putative effects of a semaphorin 5A variant, rs7702187, in the context of Parkinson's disease. The authors conclude to a significant risk-enhancing role of this polymorphism in the western population on the grounds of data from 12 earlier case-control studies. While the OR given (0.87) is, by definition, risk-lowering, the approach taken to assessing the overall risk is a concern. To begin with, no meaningful insight is to be expected from a meta analysis that lags 4 years behind. Even so, the data collected are grossly incomplete in that some 10,600 cases and 15,233 controls are missing from publications that were available in 2010^{2,3}. Out of 15 studies collected, the authors appear to have dropped at least 6 without providing any further details. Of those studies that were retained, genotype data were extracted with errors⁴ or were added up to give incorrect allele counts^{5,6}. Methodological discrepancies have gone unnoticed, despite an earlier alert⁷. Thus, some studies have referred to "T" as the major allele^{7,8} whereas others cite "A" as the major allele^{5,6} or leave the major allele undefined⁹. Regardless of allele specifications in the original studies, the authors have arbitrarily assigned a "T" to the more frequent allele even if the data clearly pertained to allele "A"⁶. As the substitution in guestion requires additional strand information to resolve uncertainties regarding the classification as "A" or "T", the authors should have removed all studies that fail to provide such information. Hardy-Weinberg equilibrium data are missing, instead a cryptic "Quality score" of 5 is allocated to all studies retrieved. In the light of these open issues, I propose that the authors be given the opportunity to reevaluate rs7702187 in Parkinson's disease.

Conflict of Interest

The Author declares that he has no conflict of interests. The author of this study did not receive any financial support for this submission.

References

- YU X, WANG F, ZHANG JP. Meta analysis of the association of rs7702187 SNP in SEMA5A gene with risk of Parkinson's disease. Eur Rev Med Pharmacol Sci 2014; 18: 900-904.
- 2) SIMÓN-SÁNCHEZ J, SCHULTE C, BRAS JM, SHARMA M, GIBBS JR, BERG D, PAISAN-RUIZ C, LICHTNER P, SCHOLZ SW, HERNANDEZ DG, KRÜGER R, FEDEROFF M, KLEIN C, GOATE A, PERLMUTTER J, BONIN M, NALLS MA, ILLIG T, GIEGER C, HOULDEN H, STEFFENS M, OKUN MS, RACETTE BA, COOKSON MR, FOOTE KD, FERNANDEZ HH, TRAYNOR BJ, SCHREIBER S, AREPALLI S, ZONOZI R, GWINN K, VAN DER BRUG M, LOPEZ G, CHANOCK SJ, SCHATZKIN A, PARK Y, HOLLENBECK A, GAO J, HUANG X, WOOD NW, LORENZ D, DEUSCHL G, CHEN H, RIESS O, HARDY JA, SINGLETON AB, GASSER T. GENOME-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009; 41: 1308-1312.
- 3) ELBAZ A, NELSON LM, PAYAMI H, IOANNIDIS JP, FISKE BK, ANNESI G, CARMINE BELIN A, FACTOR SA, FERRARESE C, HADJIGEORGIOU GM, HIGGINS DS, KAWAKAMI H, KRÜGER R, MARDER KS, MAYEUX RP, MELLICK GD, NUTT JG, RITZ B, SAMII A, TANNER CM, VAN BROECKHOVEN C, VAN DEN EEDEN SK, WIRDEFELDT K, ZABETIAN CP, DEHEM M, MONTIMURRO JS, SOUTHWICK A, MYERS RM, TRIKALINOS TA. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol 2006; 5: 917-923.
- 4) FARRER MJ, HAUGARVOLL K, ROSS OA, STONE JT, MILKOVIC NM, COBB SA, WHITTLE AJ, LINCOLN SJ, HULIHAN MM, HECKMAN MG, WHITE LR, AASLY JO, GIBSON JM, GOSAL D, LYNCH T, WSZOLEK ZK, UITTI RJ, TOFT M. Genomewide association, Parkinson disease, and PARK10. Am J Hum Genet 2006; 78: 1084-1088.
- CLARIMON J, SCHOLZ S, FUNG HC, HARDY J, EEROLA J, HELLSTROM O, CHEN CM, WU YR, TIENARI PJ, SINGLETON A. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet 2006; 78: 1082-1084.
- 6) GORIS A, WILLIAMS-GRAY CH, FOLTYNIE T, COMPSTON DA, BARKER RA, SAWCER SJ. No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. Am J Hum Genet 2006; 78: 1088-1090.

- 7) MARAGANORE DM, DE ANDRADE M, LESNICK TG, KRISHNA PANT PV, COX DR, BALLINGER DG. Response from Maraganore et al. Am J Hum Genet 2006; 78: 1092-1094.
- 8) BIALECKA M, KURZAWSKI M, KLODOWSKA-DUDA G, OPALA G, TAN EK, DROZDZIK M. Polymorphism in semaphorin 5A (Sema5A) gene is not a marker of Parkinson's disease risk. Neurosci Lett 2006; 399: 121-123.
- LI Y, ROWLAND C, SCHRODI S, LAIRD W, TACEY K, ROSS D, LEONG D, CATANESE J, SNINSKY J, GRUPE A. A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. Am J Hum Genet 2006; 78: 1090-1092.

P.G. Sand^{1,2}

¹Department of Psychiatry, University of Regensburg, Germany ²Danuvius Klinik GmbH, Ingolstadt, Germany